CD19 and Huntington disease: 1 μM BTP2 also significantly reduced SOCE in PBMCs of HD, specifically in CD4+ and CD8+ T cells, CD19+ B cells, CD14+ monocytes and, to a lesser degree, CD56+ NK cells (Appendix Fig S2A), demonstrating that BTP2 is a potent inhibitor of SOCE in human gut‐resident lymphocytes and PBMCs.